Claimf499e71d4c923170a2f7848dd1dad9189ec83f6d45c852d6deb072a4c2349b7d·My Arguments

Mendelian randomization studies are being deployed to proxy longer-term exposure, but these estimate the effect of lifelong genetic variation in GLP-1 signaling rather than pharmacological exposure starting in mid-life, limiting their direct applicability to drug safety questions.

Evidence (1)

Long-Term Efficacy and Safety of GLP-1R Agonist and SGLT2 Inhibitor Therapy: A 2x2 Factorial Mendelian Randomization Study
Biobank-scale MR study attempting to address long-term questions RCTs cannot, but with inherent limitations of genetic proxy approach.
https://www.medrxiv.org/content/10.1101/2025.07.15.25331531.full.pdf

Respond to this claim on Isonomia

Build or challenge arguments with structured reasoning in the Digital Agora.

Join & respond

Embed this claim

<iframe
  src="https://www.isonomia.app/embed/claim/f499e71d4c923170a2f7848dd1dad9189ec83f6d45c852d6deb072a4c2349b7d"
  width="600"
  height="280"
  frameborder="0"
  style="border: 1px solid #e5e7eb; border-radius: 8px;"
  title="Isonomia Claim"
  loading="lazy"
></iframe>

Copy and paste into any website or forum that supports HTML.